ReviewClinical immunology (Orlando, Fla.)2019
Pathophysiology and inhibition of IL-23 signaling in psoriatic arthritis: A molecular insight.
Review in Clinical immunology (Orlando, Fla.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 47 citations in OpenAlex.
- Psoriatic Arthritis: Therapeutic Advances and Novel Treatment Strategies-A Scoping Review.Life (Basel, Switzerland) · 2026Review
- Receptor engineering constitutes feedback control and robustness of IL-23R signaling and highlights importance of intracellular cytokine receptor signaling motifs.Cell communication and signaling : CCS · 2026Article
- Aloesin alleviates imiquimod-induced psoriasis in dermal layers through inhibition of interleukins and NF-κB signaling pathways.Scientific reports · 2025Article
- Osteoarthritis versus psoriasis arthritis: Physiopathology, cellular signaling, and therapeutic strategies.Genes & diseases · 2024Review
- Structures of complete extracellular receptor assemblies mediated by IL-12 and IL-23.Nature structural & molecular biology · 2024Article
- Efficacy and Safety of Risankizumab in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Rheumatology and therapy · 2024Review
- Axial Spondyloarthritis: Reshape the Future-From the "2022 GISEA International Symposium".Journal of clinical medicine · 2022Review
- Structural basis of activation and antagonism of receptor signaling mediated by interleukin-27.Cell reports · 2022Article
- Tildrakizumab: Successful Response in Two Patients With Psoriatic Arthritis.Dermatology practical & conceptual · 2022Article
- IL-23 orchestrating immune cell activation in arthritis.Rheumatology (Oxford, England) · 2021Article
- Cell-penetrating Alphabody protein scaffolds for intracellular drug targeting.Science advances · 2021Article
- New treatments for PsA meet targeted therapy goals.Nature reviews. Rheumatology · 2021Article
- Skin expression of IL-23 drives the development of psoriasis and psoriatic arthritis in mice.Scientific reports · 2020Article
- IL-23, but not IL-12, plays a critical role in inflammation-mediated bone disorders.Theranostics · 2020Article
- Article
- The parallel paradigm between intestinal transplant inflammation and inflammatory bowel disease.Current opinion in organ transplantation · 2019Review
- Kuijieling-Containing Serum Regulates Th17 and Treg Cell Differentiation by Inhibiting STAT3 SignalingEvidence-based complementary and alternative medicine : eCAM · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Psoriatic arthritis (PsA) is a chronic inflammatory arthritis of unknown etiology, and currently the cellular and molecular interactions that dictate its pathogenesis remain elusive. A role of the interleukin-23 (IL-23)/IL-23R (IL-23 receptor) interaction in the development of psoriasis and PsA is well established. As IL-23 regulates the differentiation and activation of innate and adaptive immunity, it pertains to a very complex pathophysiology involving a plethora of effectors and transducers. In this review, we will discuss recent advances on the cellular and molecular pathophysiological mechanisms that regulate the initiation and progression of PsA as well as new therapeutic approaches for IL-23/IL-23R targeted therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.